Acroosteolysis in Systemic Sclerosis

Akbar, Lujayn; Akbar, Nuralhuda; Muhaish, Mona Al; Akbar, Shahrazad; Kamar, Atef

doi:10.1016/j.amjms.2018.10.005

Cited by 1 publication

(4 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The resorption or erosion of distal phalanges makes them shortening more likely to occur in bones of hands and feet, anti‐scl‐70, ANA 55 . It has a prevalence of approximately 6%−65% in SSc patients.…”

Section: Discussionmentioning

confidence: 99%

“…Following this, there is a rapid increase in receptor activator of nuclear factor kappa beta ligand (RANK‐L) (osteoblasts precursor) and monocyte colony‐stimulating factor (M‐CSF), which actively participate in the pathophysiology of the SSc 57 . It is associated with DUs, extra‐articular calcification, 58 ILD, reduced FVC, PAH, 57 Raynaud phenomenon, myocardial fibrosis, cardiac effusion, arthralgia, myositis, erectile dysfunction, arterial hypertension, erosive esophagitis, gastroesophageal reflux disease 55,59,60 …”

Section: Discussionmentioning

confidence: 99%

“…The resorption or erosion of distal phalanges makes them shortening more likely to occur in bones of hands and feet, anti‐scl‐70, ANA. 55 It has a prevalence of approximately 6%−65% in SSc patients. Chronic hypoxia plays a pivotal role in bone resorption by osteoclastogenesis, osteoclasts, osteolysis, or angiogenesis.…”

Section: Discussionmentioning

confidence: 99%

“… 57 It is associated with DUs, extra‐articular calcification, 58 ILD, reduced FVC, PAH, 57 Raynaud phenomenon, myocardial fibrosis, cardiac effusion, arthralgia, myositis, erectile dysfunction, arterial hypertension, erosive esophagitis, gastroesophageal reflux disease. 55 , 59 , 60 …”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Neurological, cardiac, musculoskeletal, and renal manifestations of scleroderma along with insights into its genetics, pathophysiology, diagnostic, and therapeutic updates

Prajjwal,

Marsool,

Yadav

et al. 2024

Health Science Reports

View full text Add to dashboard Cite

BackgroundScleroderma, also referred to as systemic sclerosis, is a multifaceted autoimmune condition characterized by abnormal fibrosis and impaired vascular function. Pathologically, it encompasses the persistent presence of inflammation, abnormal collagen buildup, and restructuring of blood vessels in various organs, resulting in a wide range of clinical symptoms. This review incorporates the most recent scientific literature on scleroderma, with a particular emphasis on its pathophysiology, clinical manifestations, diagnostic approaches, and treatment options.MethodologyA comprehensive investigation was carried out on numerous databases, such as PubMed, MEDLINE, Scopus, Web of Science, and Google Scholar, to collect pertinent studies covering diverse facets of scleroderma research.ResultsScleroderma presents with a range of systemic manifestations, such as interstitial lung disease, gastrointestinal dysmotility, Raynaud's phenomenon, pulmonary arterial hypertension, renal complications, neurological symptoms, and cardiac abnormalities. Serological markers, such as antinuclear antibodies, anti‐centromere antibodies, and anti‐topoisomerase antibodies, are important for classifying diseases and predicting their outcomes.DiscussionThe precise identification of scleroderma is crucial for promptly and correctly implementing effective treatment plans. Treatment approaches aim to improve symptoms, reduce complications, and slow down the progression of the disease. An integrated approach that combines pharmacological agents, including immunosuppressants, endothelin receptor antagonists, and prostanoids, with nonpharmacological interventions such as physical and occupational therapy is essential for maximizing patient care.ConclusionThrough the clarification of existing gaps in knowledge and identification of emerging trends, our goal is to improve the accuracy of diagnosis, enhance the effectiveness of therapeutic interventions, and ultimately enhance the overall quality of life for individuals suffering from scleroderma. Ongoing cooperation and creative research are necessary to advance the field and achieve improved patient outcomes and new therapeutic discoveries.

show abstract

Section: Discussionmentioning

confidence: 99%